Status:
NOT_YET_RECRUITING
Exercise Training in Women With Heart Disease 2
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Cardiovascular Diseases
Coronary Heart Disease
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This study will compare the effects of two different types of training on exercise capacity in women with coronary heart disease (CHD). Participants will be randomized into either the virtual high-int...
Detailed Description
Heart disease is a leading cause of death for women. Women who suffer a heart attack are more likely than men to be inactive, have lower fitness, and die in the next year; patients also report poor me...
Eligibility Criteria
Inclusion
- Women (i.e., female sex assigned at birth) with CHD (e.g., coronary artery bypass grafting surgery \[CABG\], percutaneous coronary intervention \[PCI\], acute myocardial infarction \[MI\], MI with no obstructive coronary artery disease \[MINOCA\], or ischemia with no obstructive coronary artery disease \[INOCA\] at least 4 weeks post procedure or event; based on clinical evidence this is a safe period of time to exercise);
- Patient is able to perform a symptom limited CPET (this is the primary outcome and needed to determine peak HR for the exercise training prescription); and
- Patient is able to read and understand English or French.
Exclusion
- Patient is currently participating in routine exercise training (\>2x/week, routine exercise training is defined as a planned, structured, and repetitive exercise that is performed in order to maintain or improve physical fitness.) (this may reduce the impact of HIIT or MICT on outcomes);
- Patient has: NYHA class III-IV heart failure symptoms; unstable angina; or established diagnosis of chronic obstructive pulmonary disease, severe mitral or aortic stenosis, or hypertrophic obstructive cardiomyopathy (this may interfere with the ability to engage in MICT or HIIT);
- Patient has uncontrolled arrhythmia (this may impact the HR-based exercise training prescription and monitoring);
- Patient is unable to provide written informed consent; or
- Patient is unwilling or unable to return for follow-up visits at 12 and 26 weeks.
- Patient is unwilling to be randomized to HIIT or MICT.
Key Trial Info
Start Date :
August 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2029
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT06494163
Start Date
August 12 2024
End Date
March 30 2029
Last Update
August 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7